BETR-001

BETR-001 is a BetterLife patent protected derivative of lysergic acid diethylamide (LSD). BETR-001 is a potent neuroplastogen but is non-hallucinogenic. BETR-001 enables the brain to rewire, repair and heal itself. BETR-001 has all the therapeutic benefits of psychedelics without hallucinations and without controlled substance restrictions.

Compound Code: BETR-001

Delivery: Oral capsules

Potential Indications: Traumatic Brain Injury, PTSD, Chronic Headaches, Depression & Anxiety

Patents: Issued and Pending

Development Stage: IND enabling studies ongoing; IND and Phase 1 start projected for 2026

The BETR-001 Advantage

	BETR-001	Psilocybin	LSD	Ibogaine
CSA Schedule 1 drug	NO	Yes	Yes	Yes
Hallucinogenic effects	NO	Yes	Yes	Yes
Cardiac Safety concerns	NO	Yes	Yes	Yes
Neuroplastogen	YES	Yes	Yes	Yes
Patient self-administration	YES	No	No	No
Regulatory/Policy Hurdles	LOW	High	High	High

Historical Background (BOL-148)

When Albert Hoffman first made LSD, he also made many derivatives of LSD. One of these derivatives was 2-bromo-LSD that was coded BOL-148 by Sandoz Labs. This was tested in over 10 human trials in the 1950s. BOL-148 was found not to cause any hallucinations. It also blocked the hallucinations caused by LSD. Because BOL-148 did not cause hallucinations, it was thought to be inactive and shelved. About five decades later, a pilot study (Karst et al, Cephalgia 2010), tested BOL-148 in 5 cluster headache patients. This study found BOL-148 essentially fully cured the cluster headaches in this population. BOL-148 is normally synthesized by using LSD as starting material. Importantly, the stereochemistry of the final 2-bromo-LSD in BOL-148 is not known. 2-bromo-LSD can exist as four stereoisomers, which BetterLife has shown to have different properties.

BETR-001 Structure & Patents

2-bromo-LSD can exist as four stereoisomers. Stereoisomers, also referred to as mirror images, are different spatial forms of the same chemical structure. BetterLife discovered that only one of the four stereoisomers of 2-bromo-LSD is active against the neuroreceptors of interest. It is only this stereoisomer which is neuroplastogenic and has an excellent safety profile. This is BETR-001 and patented by BetterLife (patent is granted in US and pending in other jurisdictions). Additionally BetterLife has a patented BETR-001 synthesis pathway that does not use LSD as starting material – the whole manufacturing process is therefore not restricted by any controlled substance regulations.

BETR-001 is a Potent Neuroplastogen

Neuroreceptor studies show that BETR-001 is much more selective than LSD (Lewis et al, 2023). These studies also show that BETR-001 is a potent neuroplastogen. BETR-001 has both short and long term potent neuroplastogenic effects. BETR-001 is also seen to be effective against depression/anxiety and neuropathic pain in different preclinical models.

Growth of new dendrites in rat cortical neuronal cultures treated with either:

– No Drug

– BETR-001

BETR-001 treatment was for 3 hours; neuronal growth assessed on Day 6 after treatment.

Formation of new spines (green) in rat cortical neuronal cultures treated with either:

– No Drug

– BETR-001

– Ketamine

Drug treatment was for 3 hours; neuronal growth assessed on Day 18 after treatment.

Working together to Build a BetterLife for all.

REACH US

Burdens call for alternatives in the landscape of options ….

Challenges Facing All Stakeholders in Mental Healthcare

People

Are struggling with increased occurrences of mental health issues

Health Providers

Are challenged to keep pace with more demands for better solutions

Insurance Providers

Are strained from pressures due to increasing number of patients

Governments

Are logging higher health care costs from rising mental health problems

Adult with Depression

0 %

Do Not Receive Mental Health Treatment²

Covid Mental Strain

0 %

US Adults Are Dealing with Anxiety & Depression¹

Mental Health Spending

$ 0 Billion

Increase In Anxiety & Depression In Adults³

Pipeline and Indications Program

We are developing first-in-class, 2nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need

Our commitment, from inception to reception, is to deliver patient-centric medicines rooted on solid pharmacological principles and processes that deliver results.

The New Paradigm and it Challenges

We are developing first-in-class, 2^nd Generation, non-hallucinogenic, patient-centric therapeutics to treat various mental and neurological disorders with high unmet need

Compound Name: BETR-001

Product Name: E559 [proprietary 2-bromo-LSD compound]

Delivery: Oral, Capsule

Description: AA first-in-class, non-hallucinogenic, second-generation LSD derivative.

Indications: MDD, Anxiety, Neuropathic Pain

Patents: Issued and Pending

Compound Name: BETR-002

Product Name: Dihydrohonokiol-B (DHH-B)

Delivery: Oral Capsule

Description: A derivative of hydrohonokiol, a known anxiolytic compound.

Indications: Benzodiazepine Dependency, Anxiety, Neurodegenerative disorders

Patents: Pending

Pipeline
Program	Discovery	Preclinical	IND	Phase I	Phase II	Phase III
Major Depressive Disorder BETR-001
Anxiety Disorder BETR-001
Neuropathic Pain BETR-001
Benzodiazepine Dependency BETR-002

References

https://www.nature.com/articles/d41586-021-00175-z
https://mhanational.org/sites/default/files/2021%20State%20of%20Mental%20Health%20in%20America_0.pdf
https://finance.yahoo.com/news/why-mental-health-care-in-america-is-so-shoddy-183448311.html

Clinical Process

Study Design

Customized & Protocol Based

Drug Development

Proactive & Data Driven

Trial Execution

Transparent & Compliant

Regulatory Submission

Complete & Timely